Predictive Factors in Breast Cancer Chemotherapy
Author Information
Author(s): G MacGrogan, L Mauriac, M Durand, F Bonichon, M Trojani, I de Mascarell, JM Coindre
Primary Institution: Institut Bergonie, Comprehensive Cancer Center
Hypothesis
Can immunohistochemical markers predict tumor response to primary chemotherapy in breast invasive carcinoma?
Conclusion
The study found that clinical tumor size, estrogen receptor status, and Mibl index are significant predictors of tumor response to chemotherapy, while c-erbB-2 overexpression is a major prognostic factor for patient survival.
Supporting Evidence
- Negative estrogen receptor detection was highly correlated with chemosensitivity.
- A high percentage of Mibl-positive tumor cells was correlated with tumor responsiveness to chemotherapy.
- Initial tumor size less than 4 cm was associated with better response to treatment.
- C-erbB-2 overexpression was a significant independent prognostic factor for overall survival.
Takeaway
Doctors can use certain tests to see how well a breast cancer might respond to treatment before starting it, which helps in planning the best care.
Methodology
The study analyzed core biopsies from patients treated with primary chemotherapy, assessing various immunohistochemical markers and their correlation with tumor response and patient survival.
Limitations
The study is limited to a specific population and treatment regimen, and results may not be generalizable.
Participant Demographics
{"mean_age":53,"menopausal_status":{"premenopausal":46,"perimenopausal":13,"postmenopausal":69}}
Statistical Information
P-Value
{"ER":0.001,"Mibl":0.009,"tumor_size":0.03,"c-erbB-2_OS":0.0006,"DFI":0.03,"MFI":0.008}
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website